BioPharmaceutical Business Intelligence

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Dow
Cipla
Healthtrust
Medtronic
Julphar
Mallinckrodt
Boehringer Ingelheim
AstraZeneca
Fish and Richardson

Generated: January 21, 2018

DrugPatentWatch Database Preview

TROKENDI XR Drug Profile

« Back to Dashboard

Which patents cover Trokendi Xr, and what generic alternatives are available?

Trokendi Xr is a drug marketed by Supernus Pharms and is included in one NDA. There are nine patents protecting this drug and two Paragraph IV challenges.

This drug has eleven patent family members in eight countries.

The generic ingredient in TROKENDI XR is topiramate. There are twenty-six drug master file entries for this compound. Fifty-three suppliers are listed for this compound. Additional details are available on the topiramate profile page.

US Patents and Regulatory Information for TROKENDI XR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-002 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-001 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-004 Aug 16, 2013 RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Supernus Pharms TROKENDI XR topiramate CAPSULE, EXTENDED RELEASE;ORAL 201635-003 Aug 16, 2013 RX Yes No ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for TROKENDI XR
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Extended-release Capsules 200 mg ➤ Subscribe 4/3/2014
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, and 100 mg ➤ Subscribe 5/12/2014

International Patents for TROKENDI XR

Supplementary Protection Certificates for TROKENDI XR

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/028 United Kingdom ➤ Subscribe PRODUCT NAME: TOPIRAMATE; REGISTERED: UK 0242/0301 19950718
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Harvard Business School
McKinsey
QuintilesIMS
Boehringer Ingelheim
Johnson and Johnson
Teva
US Department of Justice
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot